Shareholders' Equity (Details) - Schedule of stock-based compensation expense - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of stock-based compensation expense [Abstract]
Research and development options expense	$ 304,421	$ 252,173
Total research and development expenses	304,421	252,173
General and administrative options expense	1,955,096	1,168,281
Stock and warrants issued to consultants and employees	1,980,900	710,792
Total general and administrative expenses	3,935,996	1,879,073
Total stock-based compensation expense	$ 4,240,417	$ 2,131,246